

### AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 45, line 10 as follows:

Specific antigen recognition by the variable domains underlies the pathogenic effects of certain antibodies (Abs). Abs<sup>+</sup> produced as a result of autoimmune, allergic and anti-transplant reactions. For instance, Abs found in myasthenia gravis (reviewed in ref. 1) and hemophilia (reviewed in ref. 2) bind important epitopes of the acetylcholine receptor and Factor VIII, respectively, which interfere with the biological activity of these proteins by a steric hindrance mechanism. Other Abs utilize their Fc region to mediate pathogenic effects but antigen recognition by Ab variable domains is the stimulus initiating these effects, e.g., Ab recognition of erythrocyte antigens stimulates complement activation by the Fc region in autoimmune hemolytic anemia and incompatible blood transfusions. Similarly, allergen recognition by IgE bound to Fc receptors on the surface of mast cells stimulates their degranulation. In other diseases, the mechanism of Ab pathogenicity is less clear. For example, Abs to nucleic acids in lupus (reviewed in ref. 3) and to thyroglobulin in Hashimoto's thyroiditis (reviewed in ref. 4) are unambiguously disease-associated, but additional immune abnormalities are also evident in these diseases, and the precise functional effects of the Abs remain debatable. Recently, a novel variable domain mechanism underlying Ab pathogenicity has emerged, viz., the catalytic cleavage of antigens. Hydrolytic catalysts such as Abs to polypeptides (5-8) and nucleic acids (9) hold the potential of permanent antigen inactivation. Moreover, catalysts are endowed with turnover capability, i.e., a single Ab molecule can hydrolyze multiple antigen molecules, suggesting that such Abs may exert functional effects that are more potent than Abs dependant on stoichiometric antigen recognition. ~~sup.1~~ Abbreviations: Ab, antibody; AMC, 7-amino-4-methylcoumarin; BSA, bovine serum albumin; CAL, covalently reactive antigen analog; DFP, diisopropyl fluorophosphate; exEGFR, extracellular domain of human epidermal growth factor receptor; KLH, keyhole limpet hemocyanin; MCA, methylcoumarinamide; V domain, variable domain; VIP, vasoactive intestinal peptide

Please amend the paragraph beginning on page 49, line 8 as follows:

**Covalent Ab Labeling.** Monoclonal Ab c23.5, raised by hyperimmunization with VIP. It is characterized by strong recognition of the ground state of VIP (K<sub>d</sub> 1.9 nM; K<sub>m</sub> 0.34 nM), made possible by traditional noncovalent Ab paratope-epitope interactions (23). The catalytic site of the Ab is located in the light chain subunit and is composed of a serine protease-like catalytic triad (15). Here, we compared the covalent binding of this Ab by VIP-CAL 3 and hapten CAL 1. The isotype-matched Ab UPC10 (IgG2a, .kappa.) served as the control to determine background Ab nucleophilic reactivity independent of noncovalent recognition of VIP. The covalent reaction was visualized by boiling the reaction mixtures

followed by denaturing SDS-electrophoresis and detection of biotin-containing adducts (FIG. 15A, inset). Accumulation of covalent VIP-CAL 3 adducts with the anti-VIP Ab increased linearly as a function of time,<sup>3</sup> (the CAL-Ab reactions are predicted to follow the second-order rate law, and linear adduct accumulation will occur in the initial stage of the reaction) with the light chain subunit accounting for the majority of the adducts (nominal mass 29 kD determined by comparison with molecular mass standards). Adducts of VIP-CAL 3 with the control Ab were formed at lower levels. Similarly, hapten CAL 1 reacted with anti-VIP and control Abs slowly compared to the VIP-CAL, and there was no preference for covalent binding of the hapten CAL at the light chain subunit. Apparent reaction velocities ( $V_{\text{sub.app}}$ ) were obtained from the slopes of linear regression curves fitted to the progress data by least square analysis ( $[Ab-CAL] = V_{\text{sub.app}} t$ , where  $[Ab-CAL]$  represents the intensity of Ab-CAL adduct band in AAU, and  $t$ , the reaction time].  $V_{\text{sub.app}}$  values are compiled in Table 5. For the anti-VIP Ab,  $V_{\text{sub.app}}$  of the VIP-CAL 3 reaction with the light chain was 6.6-fold greater than the heavy chain. Hapten CAL 1  $V_{\text{sub.app}}$  values for the two subunits of this Ab were nearly equivalent.  $V_{\text{sub.app}}$  for the reaction of VIP-CAL with the anti-VIP light chain was 66-fold greater than the corresponding reaction with the control Ab light chain. These observations indicate the selective nucleophilic reactivity of the anti-VIP light chain. Inclusion of VIP devoid of the phosphonate group in the reaction mixture inhibited the formation of VIP-CAL 3 adducts with the anti-VIP light chain (FIG. 15B; inhibition in 3 repeat experiments, 41.0+/-7%). It may be concluded that selective covalent binding of VIP-CAL 3 by the anti-VIP Ab is made possible by noncovalent interactions due to the presence of the VIP sequence.<sup>3</sup> The CAL-Ab reactions are predicted to follow the second-order rate law, but linear adduct accumulation will occur in the initial stage of the reaction.

Please amend the paragraph on page 53, line 21 as follows:

As noted previously, catalytic Abs are proposed to contribute in the pathogenesis of autoimmune disease. Specific covalent inhibitors represent a novel means to help define the precise functional effects of the Abs. Such inhibitors may serve as prototypes for development of therapeutic agents capable of ameliorating harmful Ab effects. In addition to inactivation of secreted Abs, reagents such as the VIP-CAL may be useful in targeting antigen-specific B cells. The feasibility of this goal is indicated by evidence that CALs bind covalently to Abs expressed on the surface of B cells as components of the B cell receptor.<sup>3</sup> Ab nucleophilicity may be viewed as an indication of their competence in completing the first step in covalent catalysis, i.e., formation of an acyl-Ab reaction intermediate. This is supported by observations that the magnitude of Ab nucleophilic reactivity is correlated with their proteolytic activity (31). A recent study suggests that noncatalytic Abs also contain nucleophiles but are

unable to facilitate steps in the catalytic cycle following covalent attack on the antigen, viz., water attack on the acyl-Ab intermediate and product release (31). Regardless of the physiological functions of nucleophiles expressed by noncatalytic Abs, their presence may allow CAL-targeting of Ab populations with established pathogenic roles, e.g., anti-factor VIII Abs in hemophilia.<sup>2</sup>

Please add the following paragraph to the specification after page 89, line 28:

**List of References:**

1. Schultz, P. G., and Lerner, R. A. (1995) *Science* 269, 1835-1842
2. Stewart, J. D., and Benkovic, S. J. (1995) *Nature* 375, 388-391
3. Paul, S., et. al. (1989) *Science* 244, 1158-1162
4. Shuster, A. M., et. al. (1992) *Science* 256, 665-667
5. Matsuura, K., and Sinohara, H. (1996) *Biol. Chem.* 377, 587-589
6. Lacroix-Desmazes, S., et. al. (1999) *Nat. Med.* 5, 1044-1047
7. Paul, S., et. al. (1992) *J. Biol. Chem.* 267, 13142-13145
8. Hifumi, E., Okamoto, Y., and Uda, T. (1999) *J. Biosci. Bioengin.* 88, 323-327
9. Izadyar, L., et. al. (1993) *Proc. Natl. Acad. Sci. USA* 90, 8876-8880
10. Gao, Q.-S., Sun, M., Rees, A., and Paul, S. (1995) *J. Mol. Biol.* 253, 658-664
11. Paul, S., et. al. (2001) *J. Biol. Chem.* 276, 28314-28320
12. Kolesnikov, A. V., et. al. (2000) *Proc. Natl. Acad. Sci. USA* 97, 13526-13531
13. Karle, S., Nishiyama, Y., et. al. (2003) *Vaccine* 21, 1213-1218
14. Nishiyama, Y., Taguchi, H., et. al. (2002) *Arch. Biochem. Biophys.* 402, 281-288
15. Brown, P. M., et. al. (1994) *Eur. J. Biochem.* 225, 223-233
16. Udenfriend, S., Stein, S., et. al. (1972) *Science* 178, 871-872
17. Green, N. M. (1965) *Biochem. J.* 94, 23c-24c
18. Taguchi, H., Burr, G., et. al. (2002) *Bioorg. Med. Chem. Lett.* 12, 3167-3170
19. Oleksyszyn, J., and Powers, J. C. (1994) in *Methods in Enzymology* vol. 244 (Barrett, A. J., ed.) pp. 423-441, Academic Press, New York
20. Oleksyszyn, J., Boduszek, B., et. al. (1994) *J. Med. Chem.* 37, 226-231
21. Zhao, Q., Kovach, J. M., et. al. (1994) *Biochemistry* 33, 8128-8138
22. Kalaga, R., Li, L., et. al. (1995) *J. Immunol.* 155, 2695-2702
23. Whitlow, M., Bell, B. A., et al. (1993) *Protein Eng.* 6, 989-995
24. Fersht, A. (1985) *Enzyme Structure and Mechanism*, Freeman and Company, NY
25. Gololobov, G., Sun, M., and Paul, S. (1999) *Mol. Immunol.* 36, 1215-1222

26. Zhou, G. W., Guo, J., et. al. (1994) *Science* 265, 1059-1064
27. Wuilmart, C., and Urbain, J. (1976) *J. Immunogenet.* 3:1-14
28. Jia, Y., Kappock, T. J., et. al. (2000) *Biochem.* 39, 3927-3936
29. Vocadlo, D. J., Davies, G. J., et. al. (2001) *Nature* 412, 835-838
30. Interthal, et. al. (2001) *Proc. Natl. Acad. Sci. USA* 98, 12009-12014
31. Crennell, S. J., Garman, E. F., et. al. (1996) *J. Mol. Biol.* 259, 264-280
32. Wirsching, P., Ashley, J. A., et. al. (1995) *Science* 270, 1775-1782
33. Takagi, M., Kohda, K., et. al. (1995) *FEBS Lett.* 375, 273-276
34. Nevinsky, G. A., Kit, Y. Ya., et. al. (1998) *Appl. Biochem. Biotechnol.* 75, 77-91
35. Jimenez, R., Salazar, G., et. al. (2003) *Proc. Natl. Acad. Sci. USA* 100, 92-97
36. Braden, B. C., and Poljak, R. J. (1995) *FASEB J.* 1, 9-16
37. Paul, S., Volle, D. J., et. al. (1990) *J. Biol. Chem.* 265, 11910-11913
38. Sun, M., Gao, Q. S., et. al. (1997) *J. Mol. Biol.* 271, 374-385
39. Rao, G., and Philipp, M. (1991) *J. Protein Chem.* 10, 117-122
40. Lefevre, S., Debat, H., et. al. (2001) *FEBS Lett.* 489, 25-28
41. Paul, S. (2000) in *Chemical Immunology: Catalytic Antibodies*, Vol. 77 (Paul, S., ed) pp. 1-158, S. Karger and A. G. Basel, Switzerland
42. Berisha, H. I., Bratut, M., et. al. (2002) *Pulm. Pharmacol. Ther.* 15, 121-127
43. Voice, J. K., Grinninger, C., et. al. (2003) *J. Immunol.* 170, 308-314
44. Planque S., Zhou Y.-X., et. al. (2003) *FASEB J.* 17, 136-143
45. Bermas, B. L., Petri, M., et. al. (1994) *AIDS Res. Hum. Retroviruses* 10, 1071-1077
46. Vincent, A. (2002) *Nat. Rev. Immunol.* 2, 797-804
47. Gilles, J. G., Vanzieleghem, B., et. al. (2000) *Semin. Thromb. Hemost.* 26, 151-155
48. Rekvig, O. P., and Nossent, J. C. (2003) *Arthritis Rheum.* 48, 300-312
49. Paul, S., Volle, D. J., Beach, C. M., et. al. (1989) *Science* 244, 1158-1162
50. Matsuura, K., and Sinohara, H. (1996) *Biol. Chem.* 377, 587-589
51. Lacroix-Desmazes, S., Moreau, A., et. al. (1999) *Nat. Med.* 5, 1044-1047
52. Hatiuchi, K., Hifumi, E., Mitsuda, Y., and Uda, T. (2003) *Immunol. Lett.* 86, 249-257
53. Shuster, A. M., Gololobov, G. V., et. al. (1992) *Science* 256, 665-667
54. Bangale, Y., Karle, S., et. al. (2003) *FASEB J.* 17, 628-635
55. Voice, J. K., Dorsam, G., Chan, R. C., et. al. (2002) *Regul. Pept.* 109, 199-208
56. Maggi, C. A., Giachetti, A., et. al. (1995) *Physiol. Rev.* 75, 277-322
57. Voice, J. K., Grinninger, C., et. al. (2003) *J. Immunol.* 170, 308-314

58. Berisha, H. I., Bratut, M., et. al. (2002) *Pulm. Pharmacol. Ther.* 15, 121-127
59. Gao, Q. S., Sun, M., Rees, A. R, and Paul, S. (1995) *J. Mol. Biol.* 253, 658-664
60. Oleksyszyn, J., and Powers, J. C. (1994) in *Methods in Enzymology*, (Barrett, A. J., ed) Vol. 244, pp. 423-441, Academic Press, San Diego, Calif.
61. Paul, S., Tramontano, A., et. al. (2001) *J. Biol. Chem.* 276, 28314-28320
62. Kolcsnikov, A. V., et. al. (2000) *Proc. Natl. Acad. Sci. U.S.A.* 97, 13526-13531
63. Oleksyszyn, J., Boduszek, B., et. al. (1994) *J. Med. Chem.* 37, 226-231
64. Nishiyama, Y., Taguchi, H., et. al. (2002) *Arch. Biochem. Biophys.* 402, 281-288
65. Wellings, D. A., and Atherton, E. (1997) in *Methods in Enzymology* (Fields, G. B., ed) Vol. 289, pp. 44-67, Academic Press, New York, N.Y.
66. Aletras, A., Barlos, K., et. al. (1995) *Int. J. Pept. Protein Res.* 45, 488-496
67. Paul, S., Sun, M., et. al. (1992) *J. Biol. Chem.* 267, 13142-13145
68. Paul, S., Mei, S., et. al. (1991) *J. Biol. Chem.* 266, 16128-16134
69. Sun, M., Gao, Q. S., et. al. (1997) *J. Mol. Biol.* 271, 374-385
70. Oleksyszyn, J., and Powers, J. C. (1991) *Biochemistry* 30, 485-493
71. Sampson, N. S., and Bartlett, P. A. (1991) *Biochemistry* 30, 2255-2263
72. Means, G. E. and Wu, H. L. (1979) *Arch. Biochem. Biophys.* 194, 526-530
73. Schwartz, M. (1982) *Clin. Chim. Acta* 124, 213-223
74. Marangoni, A. (2003) *Enzyme Kinetics: A Modern Approach*, Wiley and Sons, Hoboken, N.J.
75. Planque, S., Taguchi, H., et. al. (2003) *J. Biol. Chem.* 278, 20436-20443
76. Paul, S., Planque, S., et. al. (2003) *J. Biol. Chem.* 278, 20429-20435
77. Sun, M., Li, L., Gao, Q. S., and Paul, S. (1994) *J. Biol. Chem.* 269, 734-738
78. Kaartinen, M., Pelkonen, J., and Makela, O. (1986) *Eur. J. Immunol.* 16, 98-105
79. Mitchell, T. J., and Reilly, T. M. (1990) *Pept. Res.* 3, 277-281
80. Nishiyama Y, Bhatia G., et. al. *J Biol Chem* 2004 Feb. 27; 279(9):7877-83.
81. Paul S, Planque S., et. al. *J Biol Chem* 2003 May 30; 278(22):20429-20435.
82. Planque S, Taguchi H., et. al. *J Biol Chem* 2003 May 30; 278(22):20436-20443.
83. Nossal G J. B lymphocyte physiology: the beginning and the end. *Ciba Found Symp.* 1997; 204:220-31.
84. Stollar B D. *FASEB J.* 1994 Mar. 1; 8(3):337-42.
85. Stemmer C, et. al. *J Biol. Chem.* 1996 Aug. 30; 271(35):21257-61.
86. Groggel, G. (1999) *Kidney damage in autoimmune disease.* In: S. Paul (Ed) *Autoimmune Reactions.* Humana Press, Totowa, p. 249-268.

87. Yanase, et. al. (1999) Cellular entry and nuclear localization of anti-DNA antibodies. In: S. Paul (Ed) Autoimmune Reactions. Humana Press, Totowa, p. 293-304.
88. Alarcon-Segovia D, Llorente L. Clin Exp Immunol. 1983 May; 52(2):365-71.
89. Raz E, et. al. Eur J Immunol. 1993 February; 23(2):383-90.
90. Zack, et. al. (1999) Cell and nuclear penetration by autoantibodies. In: S. Paul (Ed) Autoimmune Reactions. Humana Press, Totowa, p. 305-319.
91. Shuster et. al. 1992 May 1; 256(5057):665-7.
92. Suchkov S V. Bull Exp Biol Med. 2001 April; 131(4):353-5.
93. Matsuzaki Y, Hamasaki Y, Said S I. Science. 1980 Dec. 12; 210(4475):1252-3.
94. Delgado M, Abad C., et. al. Nat. Med. 2001 May; 7(5):563-8.
95. Bangale Y, Cavill D et. al. Peptides 2002 December; 23(12):2251-7.
96. Bangale Y, Karle S., et. al. FASEB J 2003 April; 17(6):628-35.
97. Paul S, Said S I, et. al. J Neuroimmunol 1989 July; 23(2):133-42.
98. Ganea D. Adv Neuroimmunol. 1996; 6(1):61-74.
99. Dorsam G, Voice J, Kong Y, Goetzl E J. Ann N Y Acad Sci. 2000; 921:79-91.
100. Goetzl et. al. Proc Natl Acad Sci USA. 2001 Nov. 20; 98(24):13854-9.
101. Bracci-Laudiero L, Aloe L., et. al. Neurosci Lett. 1998 May 29; 248(2):97-100.
102. Blatt N B, Glick G D. Pharmacol Ther. 1999 August; 83(2):125-39.
103. Lefkowitz J B, Di Valerio R., et. al. J. Immunol. 1996 Aug. 1; 157(3):1297-305.
104. Barbas et. al. Proc Natl Acad Sci USA. 1995 Mar. 28; 92(7):2529-33.
105. Winkler et. al. Clin Exp Immunol. 1991 September; 85(3):379-85.
106. Ackroyd P C, Cleary J, Glick G D. Biochemistry. 2001 Mar. 6; 40(9):2911-22.
107. Herrmann et. al. Eur J. Immunol. 1995 July; 25(7):1897-904.
108. Straub et. al. Am Chem Soc 1982; 104:6754-6764.
109. Froehler et. al. Nucleic Acids Res. 1986 Jul. 11; 14(13):5399-407.
110. Walter J, Bode W. Hoppe Seylers Z Physiol Chem. 1983 August; 364(8):949-59.
111. Chen et. al. Arch Biochem Biophys. 1995 Sep. 10; 322(1):198-203.
112. Taguchi et. al. Bioorg Med Chem Lett 2002 Nov. 4; 12(21):3167-70.
113. Nishiyama et. al. Arch Biochem Biophys 2002 Jun. 15; 402(2):281-8.
114. Pisetsky D S, Gonzalez T C. Clin Exp Immunol. 1999 May; 116(2):354-9.
115. Tawfik et. al. Proc Natl Acad Sci USA 1995 Mar. 14; 92(6):2145-9.
116. Licht et. al. Arthritis Rheum. 2001 June; 44(6):1320-30.

117. Desai D D, Marion T N. Induction of anti-DNA antibody with DNA-peptide complexes. *Int Immunol*. 2000 November; 12(11):1569-78.
118. Napirei M, Karsunky H, et. al. *Nat. Genet*. 2000 June; 25(2):177-81.
119. Voice, et. al. 2002 Experimental Biology Meeting, Apr. 20, 2002, New Orleans, La.
120. Paul S. Catalytic activity of anti-ground state antibodies, antibody subunits, and human autoantibodies. *Appl Biochem Biotechnol*. 1994 May; 47(2-3):241-53; 253-5.
121. Paul, S. Protein engineering. In *Molecular Biotechniques*. Ed., Walker J. (Humana Press, Totowa, N.J.). Chapter 43, pp 547-566, 1998.
122. Oleksyszyn J, Powers J C. *Methods Enzymol* 1994; 244:423-41.
123. Sampson N S, Bartlett P A. *Biochemistry* 1991 Feb. 26; 30(8):2255-63.
124. Paul et. al. *J Biol Chem* 2001 Jul. 27; 276(30):28314-20.
125. Kolesnikov et. al. *Proc Natl Acad Sci USA* 2000 Dec. 5; 97(25):13526-31.
126. Goodnow C C. *Ciba Found Symp* 1997; 204:190-202; discussion 202-207.
127. Nossal G J. *J Exp Med*. 1996 May 1; 183(5):1953-6.
128. Kohler H, Paul S. *Immunol Today* 1998; 19:221-227.
129. Paul S, Volle D J, et. al. *Science* 1989 Jun. 9; 244(4909):1158-62.
130. Gao Q S, Sun M, Rees A R, Paul S. *J Mol Biol* 1995 Nov. 10; 253(5):658-64.
131. Lacroix-Desmazes S, Moreau A, et. al. *Nat Med* 1999 September; 5(9):1044-7.
132. Oleksyszyn J, Powers J C. *Methods Enzymol* 1994; 244:423-41.
133. Planque et. al. *J Biol Chem* 2003 May 30; 278(22):20436-20443.
134. Paul et. al. Y. *J Biol Chem* 2003 May 30; 278(22):20429-20435.
135. Vincent A. *Nat Rev Immunol* 2002 October; 2(10):797-804.
136. Gilles et. al. *Semin Thromb Hemost*. 2000; 26(2): 151-5.
137. Rekvig O P, Nossent J C. *Arthritis Rheum* 2003 February; 48(2):300-12.
138. Tomer Y. *Clin Immunol Immunopathol* 1997 January; 82(1):3-11.
139. Nossal G J. *Ciba Found Symp*. 1997; 204: 220-30.
140. Lacroix-Desmazes et. al. *Haemophilia* 2002 May; 8(3):273-9.
141. Healey J F, Lubin I M, et. al. *J Biol Chem* 1995 Jun. 16; 270(24):14505-9.
142. Nishiyama et. al. *Arch Biochem Biophys* 2002 Jun. 15; 402(2):281-8.
143. Prasad et. al. *Science*. 1999 Oct. 8; 286(5438): 287-90.
144. Stallwood et. al. *J Biol Chem* 1992 Sep. 25; 267(27):19617-21.
145. Liu M A, Liu T. *J Clin Invest* 1988; 82; 2176-80.
146. Ward R H, Capon D J, Jeff C M, et al. *Nature* 1991; 352; 434-6.

147. Daar E S, Li X L, Moudgil T, Ho D D. *Proc Natl Acad Sci USA* 1990; 87: 6574-8.
148. Dowd C S, Leavitt S, Babcock G, et al. *Biochemistry* 2002; 41: 7038-46.
149. D'Souza M P, Geyer S J, et. al. *Aids* 1994; 8: 169-81.
150. Center R J, Earl P L, et. al. *J Virol* 2000, 74(10): 4448-4455.
151. Paul S, Planque S, et. al. *J Biol Chem* 2003 May 30; 278(22):20429-20435.
152. Oleksyszyn J, Boduszek B, et. al. *J Med Chem* 1994, 37(2): 226-231.
153. Green N M. *Biochem J* 1965, 94: 23c-24c.
154. Udenfriend S, Stein S, et. al. *Science* 1972, 178: 871-872.
155. Planque S, Taguchi H, et. al. *J Biol Chem* 2003 May 30; 278(22):20436-20443.
156. Burton D R, Moore J P. *Curr Opin Immunol* 2002, 14(4): 495-502.
157. Moore J P, Burton D R. *Nat Med* 1999; 5(2): 142-144.
158. Letvin N L, Barouch D H, Montefiori D C. *Annu Rev Immunol* 2002, 20: 73-99.
159. Wrin T, Nunberg J H. *AIDS* 1994, 8(11): 1622-1623.
160. Mascola J R, Snyder S W, et. al. *J Infect Dis* 1996, 173(2): 340-348.
161. Connor R I, Korber B T, et. al. *J Virol* 1998, 72(2): 1552-1576.
162. Belshé R B, Gorse G J, et. al. *AIDS* 1998, 12(18): 2407-2415.
163. Fouts T R, Binley J M, et. al. *J Virol* 1997, 71(4): 2779-2785.
164. Fouts et. al. *AIDS Res Hum Retroviruses* 1998, 14(7): 591-597.
165. Moore et. al., *J Virol* 1995, 69(1): 101-109.
166. Karle S, Planque S, et. al. *AIDS* 2004, 18:329-347
167. Gelderblom H R, Reupke H, Pauli G. *Lancet*. 1985, 2(8462): 1016-1017.
168. McKeating J A, McKnight A, Moore J P. *J Virol* 1991, 65(2): 852-860.
169. Berman P W, Nunes W M, Haffar O K. *J Virol* 1988, 62(9): 3135-3142.
170. Earl et. al. *J Virol* 1994, 68(5): 3015-3026.
171. Earl P L, Koenig S, Moss B. *J Virol* 1991, 65(1): 31-41.